Authors
Loading...
Preclinical model demonstrates that A2AR antagonists can improve survival in DLBCL via tumor immunity mechanisms.
McGaskey et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: